The short version of bremelanotide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-11. Anything still debated is marked as such rather than presented as settled.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
The War Office has referred to several British government organisations throughout history, all relating to the army. It was a department of the British Government responsible for the administration of the British Army between 1857 and 1964, at which point its functions were transferred to the new Ministry of Defence (MoD). It was equivalent to the Admiralty at that time, which was responsible for the Royal Navy (RN), and (much later) the Air Ministry, which oversaw the Royal Air Force (RAF). The name 'Old War Office' is also given to the former home of the department, located at the junction of Horse Guards Avenue and Whitehall in central London. The landmark building was sold on 1 March 2016 by HM Government for more than £350 million, on a 250-year lease, for conversion into a luxury hotel and residential apartments. Prior to 1855, 'War Office' signified the office of the Secretary at War. In the 17th and 18th centuries, a number of independent offices and individuals were responsible for various aspects of Army administration. The most important were the Commander-in-Chief of the Forces, the Secretary at War, and the twin Secretaries of State; most of whose military responsibilities were passed to a new Secretary of State for War in 1794.
== Discovery == In 2004 Linda B. Buck and Richard Axel won the Nobel Prize in Physiology or Medicine for their work on olfactory receptors. In 2006, it was shown that another class of odorant receptors – known as trace amine-associated receptors (TAARs) – exist for detecting volatile amines. Except for TAAR1, all functional TAARs in humans are expressed in the olfactory epithelium. A third class of olfactory receptors known as vomeronasal receptors has also been identified; vomeronasal receptors putatively function as pheromone receptors. As with many other GPCRs, there is still a lack of experimental structures at atomic level for olfactory receptors and structural information is based on homology modeling methods. In 2023 the structure of OR51E2 was found, the first elucidation of the structure of any human olfactory receptor. The limited functional expression of olfactory receptors in heterologous systems, however, has greatly hampered attempts to deorphanize them (analyze the response profiles of single olfactory receptors) This was first completed by genetically engineered receptor, OR-I7 to characterize the "odor space" of a population of native aldehyde receptors.
ISBN 1-871-08281-1. Scruton, Roger. Fools, Frauds and Firebrands: Thinkers of the New Left. New York: Bloomsbury US, 2015. Sherer, Daniel. "Adorno's Reception of Loos: Modern Architecture, Aesthetic Theory, and the Critique of Ornament," Potlatch 3 (Spring 2014), 19–31
Sources: en.wikipedia.org
Díaz Herrera considered using the uproar around Spadafora to seize power during a brief period that Noriega was traveling outside the country, but despite mobilizing some troops, eventually decided against following through with the coup, realizing he could not count on sufficient support. Furthermore, Noriega had made a deal with his deputy, to the effect that he would step down as military leader in 1987 and allow Díaz Herrera to succeed him. In 1987, however, Noriega went back on this agreement, announced he would be heading the military for the next five years, and assigned Díaz Herrera to a diplomatic post. Díaz Herrera retaliated by making public statements accusing Noriega of rigging the 1984 election, murdering Spadafora, and of trafficking in drugs, as well as of assassinating Torrijos with a bomb on his plane. Díaz Herrera's statements provoked huge protests against Noriega, with 100,000 people, approximately 25% of the population of Panama City, marching in protest on June 26, 1987. As with Spadafora's murder, these incidents strengthened and brought together the internal opposition to Noriega. Noriega charged Díaz Herrera with treason, and cracked down hard on the protesters. The U.S. Senate passed a resolution asking Noriega to step down until Díaz Herrera could be tried; in response Noriega sent government workers to protest outside the U.S. embassy, a protest which quickly turned into a riot. As a result, the U.S. suspended all military assistance to Panama, and the CIA stopped paying Noriega a salary.
Bain de Soleil was an American brand of sunscreen that was produced by Bayer. The brand was known for low-SPF products that were typically marketed to women seeking skin tanning. It was affiliated with the Coppertone brand. The name Bain de Soleil is French for "sun bathing." The brand used the slogan "Welcome to a place more colorful." In the 1970s and 1980s, the brand used the slogan (especially featured in television commercials) "Bain de Soleil, for the St. Tropez tan." The brand was discontinued in December 2019.
It was also formerly used in veterinary medicine as a general anesthetic but is not considered acceptable for anesthesia or euthanasia of small animals owing to adverse effects. It is also still used as a sedative prior to EEG procedures, as it is one of the few available sedatives that do not suppress epileptiform discharges. In therapeutic doses for insomnia, chloral hydrate is effective within 20 to 60 minutes. In humans it is metabolized within 7 hours into trichloroethanol and trichloroethanol glucuronide by erythrocytes and plasma esterases and into trichloroacetic acid in 4 to 5 days. It has a very narrow therapeutic window making this drug difficult to use. Higher doses can depress respiration and blood pressure. Tolerance to the drug develops after a few days of use.
== See also == Alpha nuclide List of nuclides Table of nuclides Isotope geochemistry Radionuclide Mononuclidic element Monoisotopic element Stable isotope List of elements by stability of isotopes Big Bang nucleosynthesis
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.